Hematopoietic cell lineages

Hematopoietic cell lineages refer to the developmental hierarchy of blood cells originating from multipotent hematopoietic stem cells (HSCs) in the bone marrow. This system branches into two primary lineages: the myeloid lineage, which produces erythrocytes, megakaryocytes, granulocytes, and monocytes, and the lymphoid lineage, which gives rise to B cells, T cells, and natural killer cells (Jagannathan-Bogdan & Zon, 2013). The regulation of these lineages is critical for maintaining homeostasis, immunity, and oxygen transport, and is governed by specific growth factors and cytokines such as erythropoietin and granulocyte colony-stimulating factor (Orkin & Zon, 2008). While not a single molecular target, the hematopoietic system is a central focus in pharmacology, where drugs are designed to either stimulate cell production (e.g., in anemia or neutropenia) or eliminate malignant cell populations (e.g., in leukemia). Therapeutic challenges often involve managing off-target myelosuppression or immune-related adverse events resulting from the disruption of these delicate cellular balances (NIH, 2023).

Other names

HematopoiesisBlood cell developmentHematopoietic systemHematopoietic hierarchy

Drugs interacting with hematopoietic lineages typically act by stimulating lineage-specific progenitor cells via cytokine receptor agonism (e.g., G-CSF, EPO) or by depleting specific cell populations using monoclonal antibodies or cytotoxic agents.